eyelids, face, lips; skin rash to prescriber immediately
• To notify prescriber if pregnancy is planned or suspected; to use contraception while taking product
• **Risk of medication overuse:** do not use for abortive headache treatments more than 10 days/month (ergotamines, triptans, opioids or combinations)
• **Nasal spray:** to use 1 spray in 1 nostril; may repeat if headache returns; not to repeat if pain continues after 1st dose
• To have a dark, quiet environment
• To avoid hazardous activities if dizziness, drowsiness occur
• To avoid alcohol; may increase headache
• To use SUBCUT inj technique, nasal route if prescribed
• That product does not reduce number of migraines; to be used for acute migraine; to use as symptoms occur
• **Nasal powder:** Use in each nostril using nosepiece and mouthpiece
• **SUBCUT:** provide pamphlet from manufacturer, review with patient

⚠ HIGH ALERT

SUNItinib (Rx)

(soo-nit′-in-ib)

Sutent

Func. class.: Antineoplastic—miscellaneous
Chem. class.: Protein-tyrosine kinase inhibitor

ACTION: Inhibits multiple receptor tyrosine kinases (RTKs); some are responsible for tumor growth

USES: Gastrointestinal stromal tumors (GIST) after disease progression or intolerance to imatinib; advanced renal carcinoma, pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced/metastatic disease

CONTRAINDICATIONS: Pregnancy, breastfeeding, hypersensitivity

Precautions: Children, geriatric patients, active infections, QT prolongation, torsades de pointes, stroke, heart failure

Black Box Warning: Hepatotoxicty

DOSAGE AND ROUTES

Gastrointestinal stromal tumors (GIST)/renal cell cancer
• **Adult: PO** 50 mg/day × 4 wk, then 2 wk off; may increase or decrease dose by 12.5 mg; if administered with CYP3A4 inducers, give 87.5 mg/day; if given with CYP3A4 inhibitors, give 37.5 mg/day

Pancreatic neuroendocrine (pNET)
• **Adult: PO** 37.5 mg daily continuously, increase or decrease by 12.5 mg based on tolerance, avoid potent CYP3A4 inhibitors/inducers; if used with CYP3A4 inhibitors, decrease SUNItinib dose to minimum of 25 mg/day; if used with CYP3A4 inducers, increase SUNItinib to max 62.5 mg/day

Available forms: Caps 12.5, 25, 37.5, 50 mg

Administer:
• With meal and large glass of water to decrease GI symptoms
• Store at 25° C (77° F)

SIDE EFFECTS

CNS: Headache, dizziness, insomnia, fatigue, reversible posterior leukoencephalopathy syndrome (RPLS)
CV: Hypertension, left ventricular dysfunction, QT prolongation, torsades de pointes, thrombotic microangiopathy, cardiac arrest, thromboembolism
ENDO: Hypo/hyperthyroidism
GI: *Nausea,* hepatotoxicity, vomiting, dyspepsia, *anorexia, abdominal pain,* altered taste, *constipation,* stomatitis, mucositis, pancreatitis, diarrhea, GI bleeding/perforation
GU: Nephrotic syndrome
HEMA: Neutropenia, thrombocytopenia, hemolytic anemia, leukopenia
INTEG: *Rash, yellow skin discoloration,* depigmentation of hair or skin, alopecia, necrotizing fasciitis, pyoderma gangrenosum